source
- FDA approves Eli Lilly's oral SERD Inluriyo combo for second-line metastatic breast cancerThe FDA has given approval to a new combination therapy from Eli Lilly that includes its oral selective estrogen receptor degrader, Inluriyo, for patients with metastatic breast cancer who have pro…
- China unveils five-year plan to grow biotech sector from $3M to $522B by 2030China's Ministry of Industry and Information Technology released a new five-year biotech plan that sets out ambitious growth targets for the sector. The plan aims to expand the industry from rough…